by Sue Robbins | Jan 4, 2021 | Migraine
“I hope that in six months or so from now that we will be the first oral CGRP with the indication for the prevention of migraine,” Biohaven Pharmaceutical CEO Vlad Coric told CNBC. “Patients deserve to know that they can also prevent their next...
by Sue Robbins | Dec 14, 2020 | Migraine
Monoclonal antibodies and small-molecule antagonists that target CGRP or its receptor are already having a big impact on migraine. But they have the potential to do so much more. Peter Goadsby sat in the audience, intrigued. The Australian medical student had come to...
by Sue Robbins | Nov 23, 2020 | Migraine
Therapy options for patients with migraines have expanded over the past couple of years, with several new drug classes specific to the disorder. Leading migraine experts discuss how they decide to choose one therapy over another. Treatment options for migraine have...
